EcoDrugPlus

Matrix Metallopeptidase 9

Ensembl ID : ENSBSLG00000004091
Gene Symbol: MMP9
3 Cross references
216 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSBSLG00000010039
Gene Symbol: LOC114844813
3 Cross references
198 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSBSLG00000010388
Gene Symbol: LOC114850074
3 Cross references
199 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSBSLG00000010259
Gene Symbol: MTOR
3 Cross references
222 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSBSLG00000000703
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSBSLG00000021537
Gene Symbol: MC4R
1 Cross references
211 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSBSLG00000005077
Gene Symbol: LOC114853312
2 Cross references
212 Possible Orthologues:

Melatonin Receptor 1a A

Ensembl ID : ENSBSLG00000000881
Gene Symbol: MTNR1AA
1 Cross references
190 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSBSLG00000007582
Gene Symbol: MME
3 Cross references
234 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSBSLG00000014228
Gene Symbol: LOC114855212
3 Cross references
210 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSBSLG00000013338
Gene Symbol: LOC114857731
3 Cross references
212 Possible Orthologues:

Metabotropic Glutamate Receptor 4-Like

Ensembl ID : ENSBSLG00000015263
Gene Symbol: LOC114858214
2 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).